Gilead Sciences Inc (GILD) Daily/Weekly Backtest Results

Calculations for Gilead Sciences

Expectancy is the percentage profit or loss you would expect to make on the next purchase of this stock with an entry point at the specified signal and profit target as set above. Given a large enough sample size, a positive expectancy indicates the trading strategy is likely to be profitable.

Expectancy calculation for 41 signal(s) occurring before 08 May 2024 for a 7.5% profit target: (68.29% * 8.56%) + (24.39% * 1.28%) - (7.32% * 15.77%) = 5.00%.
Wins: 28 Breakevens: 10 Losses: 3

To even out CAGR calculations, large individual returns from particularly quick trades have been capped at 300%.

The Sharpe Ratio calculation assumes a risk free return rate of 2% per calendar year. Ideally the ratio should be a positive number. A higher positive number indicates the strategy has a more attractive risk adjusted rate of return for this particular buy signal and stock over the chart's timeframe.

Gilead Sciences Analysis

Market sector: Healthcare.

External links: Seeking Alpha Research, Zacks Research.

These links may show useful information about why a stock's price has fallen significantly.

MegaDump Lite Backtest Summary (Fixed Profits System)

This table summarises how profitable it would have been to have bought this stock at each MegaDump Lite entry signal. Hover over the icons to see more details of the particular trade, including the maximum percentage drawdown and how long it took to reach the desired percentage profit.

Key:   disabled_by_default = profit point not achieved. select_check_box = profit point achieved with CAGR above 15%.
select_check_box = profit point achieved with CAGR of between 5% and 15%. select_check_box = profit point achieved but CAGR was less than 5%.

The data for Gilead Sciences Inc (exchange: XNAS symbol: GILD) was last updated 15 May 2026 23:40. Data for this stock is available from 01 Dec 2015 - 15 May 2026.